FOI Request 1132-1819 in relation to Scheduling of Thymosin
The request is for the following:
“…the request submitted to the TGA for Scheduling of Thymosin Beta 4 and Tb500 as indicated in the link below.
I am requesting specifically access to the application for inclusion of Thymosin Beta 4 and Tb500 on the Schedules List. I would request all supporting data that was
presented in the application that supports the claims.
Any/all clinical and scientific evidence that supports the claims of performance and image enhancement.
Any evidence that supports any medical benefit at all from the use of Thymosin Beta 4 or Tb500.
I would ask for clarification on what appears to be a contradiction in the rationale for the acceptance of the application. The reasons state limited evidence of therapeutic
benefits, not registered anywhere in the world (by definition no clinical evidence of efficacy or safety), experimental and yet it is accepted as being performance and image
Schedule of Relevant Documents
Doc. Folder Number
of the Act
Release in ful
paper for ACMS #16